Publications

497 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

Advice - Extension of reimbursement conditions for lumacaftor/ivacaftor (Orkambi®)

The National Health Care Institute has investigated whether the reimbursement conditions of lumacaftor in combination with ...

Report | 11-12-2023
GVS advice empagliflozin (Jardiance®) expansion List 2 conditions for chronic kidney disease

The National Health Care Institute has assessed whether the reimbursement conditions for empagliflozin (Jardiance®) can be ...

Report | 07-12-2023
Monitoring the vitamin D package measure

The Minister of Health, Welfare and Sport (VWS) decided to discontinue the reimbursement of all vitamin D products containing ...

Report | 01-12-2023
Update advice on the lock procedure for the medicinal product atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to renegotiate the price of ...

Report | 01-12-2023
Final report – Case study phase ROR DGM

The Dutch National Health Care Institute presents its vision on data availability in healthcare, based on 4 completed case ...

Report | 30-11-2023
GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

The National Health Care Institute has assessed whether latanoprost in combination with netarsudil (Roclanda®) can be included in ...

Report | 22-11-2023
Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

The National Health Care Institute has assessed whether emicizumab (Hemlibra®) can be reimbursed from the basic health care ...

Report | 16-11-2023
Orphan drug arrangement givosiran (Givlaari®) for the treatment of acute hepatic porphyria

Agreements have been made to promote appropriate use of givosiran (Givlaari®) as treatment of acute hepatic porphyria, a rare ...

Publication | 24-10-2023
Conditional inclusion procedure for medicinal products

This document describes the conditional inclusion procedure for orphan drugs, conditionals and exceptionals.

Publication | 29-09-2023
Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

The National Health Care Institute advises the Minister of Health, Welfare and Sport (VWS) to designate teduglutide (Revestive®) ...

Report | 21-09-2023

Publications

497 publications

Advice - Extension of reimbursement conditions for lumacaftor/ivacaftor (Orkambi®)

GVS advice empagliflozin (Jardiance®) expansion List 2 conditions for chronic kidney disease

Monitoring the vitamin D package measure

Update advice on the lock procedure for the medicinal product atidarsagene autotemcel (Libmeldy®) for the treatment of metachromatic leukodystrophy (MLD)

Final report – Case study phase ROR DGM

GVS advice on latanoprost/netarsudil (Roclanda®) for the treatment of glaucoma and ocular hypertension

Package advice lock procedure product emicizumab (Hemlibra®) for the treatment of moderate haemophilia A

Orphan drug arrangement givosiran (Givlaari®) for the treatment of acute hepatic porphyria

Conditional inclusion procedure for medicinal products

Advice on a possible candidate for the conditional inclusion of teduglutide (Revestive®)

Go to